I finally found a legitimate use for my California mobile driver’s license (mDL) this afternoon.
Ontario International Airport (ONT) allows people without tickets to reserve a day pass to see departing passengers off. The day pass functions as the equivalent of a real passenger’s boarding pass…with appropriate identification.
Both the day pass and my mDL were in my smartphone wallet, so all went smoothly. I wasn’t paying enough attention to know if the Transportation Security Administration (TSA) compared my live face to my mDL, but they probably did.
And I can confirm that Richard Reid rule is gone: no shoe removal required. Belts are another matter.
Are you a technology marketing leader, struggling to market your products to your prospects for maximum awareness, consideration, and conversion?
I’m John E. Bredehoft. For over 30 years, I’ve created strategy and tactics to market technical products for over 20 B2B/B2G companies and consulting clients.
For the past few months I have been posting some of Bredemarket’s reels on Flip, but my (mostly) business-related reels didn’t resonate with Flip’s consumer-oriented audience.
(Which makes my posting life easier, to be honest, but I will keep the app on my phone for a bit just in case someone with money buys the company’s assets.)
Is Instagram next?
No, seriously.
What if you based your entire business model on a single social media channel…and it suddenly disappeared?
I last discussed Syneos Health on August 15, in a popular post on early stage commercialization. When I checked for recent news I discovered that Syneos Health received a commercialization setback in India for the QL2107 Injection.
[T]he Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has rejected its Phase III clinical trial proposal for QL2107 Injection….
After detailed deliberation, the committee opined that, “the proposed clinical trial is focused completely on Pharmacokinetic (pK) parameters. Moreover, primary objective and secondary objective of phase-III study protocol has not been demonstrated for confirmation of therapeutic benefit and efficacy end point. Hence, the committee didn’t recommend to conduct the clinical trial in India.”
So what is the QL2107 Injection? First off, it comes from a Chinese company.
Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations….Dedicated to offering more affordable medicines to the world and improving people’s well-being, Qilu has exported its products to over 100 countries.
The literature on QL2107 repeatedly refers to Qilu Pharmaceutical rather than Syneos Health. But presumably there’s a partnership somewhere.
According to this website, QL2107 is a “pembrolizumab biosimilar,” a fancy way to say that it is similar to pembrolizumab (brand name Keytruda®), a monoclonal antibody with possible anti-cancer applications. It’s already undergone clinical trials.
But a Phase III clinical trial is special. The Gilead Clinical Trials website defines the four phases of clinical trials, including the third:
Phase 3 trials continue to evaluate a treatment’s safety, effectiveness, and side effects by studying it among different populations with the condition and at different dosages. The potential treatment is also compared to existing treatments, or in combination with other treatments to demonstrate whether it offers a benefit to the trial participants. Once completed, the treatment may be approved by regulatory agencies.
Although there is a fourth phase, continuous monitoring, that is obviously important.
Imagen 4.
In summary, QL2107 is not a home run or even a triple. At least in India, it’s stuck at second.
Whether you’re a marketer, a biometric expert, a technologist, or just someone scrolling the webs, you can feel a variety of emotions after reading a Bredemarket blog post.
Maybe amused.
Maybe informed,
Maybe empowered.
But some will experience more powerful emotions.
For a targeted few who find themselves paralyzed, maybe afraid. Afraid that your competitors will steal your prospects unless you act.
Or for those targeted few who despise powerlessness and want to act, maybe hungry. Hungry to get your product’s benefits to your prospects so they convert.
I have to be honest. Some of the people who are inspired to act are perfectly capable of acting on their own. Because they’re not complete unknowns.
But others can use the help of an outside consultant such as Bredemarket.
Content, proposals, analysis. I can help with all of them.
I love how Biometric Update bundles a bunch of stories into a single post. Chris Burt outdid himself on Wednesday, covering a slew of stories regarding use and possible misuse of facial recognition by Texas bounty hunters, the NYPD, and cities ranging from Chicago, Illinois to Houlton, Maine.
But those stories aren’t the ones that I’m focusing on. Before I get to my focus, I want to go off on a tangent and address something else.
What I didn’t expect was that competition would arise between me and my bot. I’m writing these words on August 27, two days before the first Bredebot post appears, and I’m already feeling the heat.
What if Bredebot’s posts receive more traffic than the ones I write myself? What does that mean for my own posts…and for the whole premise of hiring Bredemarket to write for others?
I’m treating this as a challenge, vowing to outdo my fast bot counterpart.
And in that spirit, let’s revisit Milwaukee.
Give us any chance, we’ll take it
Access.
When Biometric Update initially visited Milwaukee in its April 28 post, the main concern was the possible agreement for the Milwaukee Police Department to provide “access” to facial data to the company Biometrica in exchange for facial recognition licenses. I subsequently explored the data issue in my own May 6 guest post for Biometric Update.
Vendors must disclose responsible uses of biometric data.
But today the questions addressed to Milwaukee don’t focus on the data, but on the use of facial recognition itself. The Biometric Update article links to a Wisconsin Watch article with more detail. The arguments are familiar to all of you: facial recognition is racist, facial recognition is sometimes relied upon as the sole piece of evidence, facial recognition data can be sent to ICE, and facial recognition can be misused.
However, before Milwaukee’s Common Council can approve facial recognition use, one requirement has to be met.
“Since the passage of Wisconsin Act 12, the only official way to amend or reject MPD policy is by a vote of at least two-thirds of the Common Council, or 10 members.
“However, council members cannot make any decision about it until MPD actually drafts its policy, often referred to as a “standard operating procedure.”
“Ald. Peter Burgelis – one of four council members who did not sign onto the Common Council letter to Norman – said he is waiting to make a decision until he sees potential policy from MPD or an official piece of legislation considered by the city’s Public Safety and Health Committee.”
The Milwaukee Police Department agrees that such a policy is necessary.
“MPD has consistently stated that a carefully developed policy could help reduce risks associated with facial recognition.
“’Should MPD move forward with acquiring FRT, a policy will be drafted based upon best practices and public input,’ a department spokesperson said.”
An aside from my days at MorphoTrak, when I would load user conference documents into the CrowdCompass mobile app: one year the topic of law enforcement agency facial recognition policies was part of our conference agenda. One agency had such a policy, but the agency would not allow me to upload the policy into the CrowdCompass app. You see, the agency had a policy…but it wasn’t public.
Needless to say, the Milwaukee Police Department’s draft policy WILL be public…and a lot of people will be looking at it.
This may mean nothing. On the one hand, Davidson had been with the company a long time, having joined Oracle in 1988 AFTER a career in the US Navy as a civil engineer. So perhaps she just retired.
Then again, Larry Ellison is 81 years old, so people don’t HAVE to retire.
And it appears that Davidson’s departure wasn’t announced in a press release, but was buried in a June filing.
The one word associated with Davidson is the word “unbreakable.”
“[D]uring a 2002 interview with Businessweek, she described the challenges of making sure the firm’s products lived up to a marketing campaign envisioned by Ellison that touted the company’s products as ‘unbreakable’….She explained at that time, saying, ‘‘Unbreakable’ gives us something to live up to,’ adding, ‘It really does concentrate the mind wonderfully. The general thought is don’t embarrass the company. Nobody wants to be the group that makes us violate it.'”
(And yes, the red glow in the unbreakable oracle in the picture is intentional. If you have ever attended a San Francisco Oracle OpenWorld with hundreds of red and white banners, you’ll understand…)
If you compete with Zoominfo, you have to understand Zoominfo…so you can exploit its weaknesses.
Highlights from the Zoominfo podcast
I could have listened to a long podcast with CEO Henry Schuck to understand the company’s weaknesses, but I didn’t have to because Matthew Robinson provided a time-stamped list of highlights. Or maybe Robinson didn’t do it himself, because Robinson is no longer necessary.
This first one caught my attention as the biometric product marketing expert, for obvious reasons.
(13:34) How they automated product marketing: From 26 people translating product info into content, down to 2 people managing AI agents.
Basically, mining data and auto-creating content.
And this second one just plain caught my attention.
(27:32) When you know the AI pressure is working: His CMO literally dreamed she disappointed him because her kids weren’t AI algorithms yet.
It’s good to know that Zoominfo has a distracted CMO. And that the CEO thinks it’s funny.
When Zoominfo’s headcount hits zero
And it’s awfully amusing that 24 product marketers lost their jobs. Remember the claims that AI wouldn’t replace you, but would let you do your job better? Lies.
Zoominfo’s business, by the way, is providing information on companies and the people who work for them. And as companies like Zoominfo right size, there is less demand for their services.
And that’s when Zoominfo will eliminate the position of the CMO and automate it.
Bredemarket 